Clinical Trials Browser

Phase 1 × Withdrawn × Squamous Cell Carcinoma of Head and Neck × Clear all

Squamous Cell Carcinoma of Head and Neck

NCT06357858 2024-07-03

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Phase 1 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05472506 2024-03-15

Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer

Phase 1 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04892875 2023-11-30

PANTHEoN

Phase 1 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Pharyngeal Neoplasms

NCT01332279 2023-04-04

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Phase 1 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT05393635 2022-12-20

DELTA-2

Phase 1 Withdrawn

GynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms

NCT02686008 2020-01-13

Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

Phase 1 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03575234 2019-08-28

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

Phase 1 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02993991 2017-12-29

PRIMED-001

Phase 1 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02211027 2017-09-07

Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA

Phase 1 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00937417 2017-04-24

S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

Phase 1 Withdrawn

BreastCNSEndocrineGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Breast Neoplasms, Male, Thyroid Carcinoma, Anaplastic

NCT02567396 2017-04-24

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Phase 1 Withdrawn

BreastGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01728480 2013-12-11

Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy

Phase 1 Withdrawn

Head & NeckOther

Squamous Cell Carcinoma of Head and Neck, Tongue Neoplasms, Mucositis

NCT00006106 2013-07-10

ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer

Phase 1 Withdrawn

Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasms, Oropharyngeal Neoplasms

Clinical Trials

Antitumor-B KAC PK Study

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer

PANTHEoN

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

DELTA-2

Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

PRIMED-001

Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA

S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy

ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer